Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Peginterferon alfa-2a - Roche

Drug Profile

Peginterferon alfa-2a - Roche

Alternative Names: PEG IFN-α-2a; PEG interferon-α-2a; Pegasys; Pegferon; Pegylated interferon-alpha-2a; R 442; RG 442; RG 964; RO 25-8310; RO 253036

Latest Information Update: 28 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Roche
  • Developer Chugai Pharmaceutical; Icahn School of Medicine at Mount Sinai; Roche; University of Pennsylvania
  • Class Antineoplastics; Antivirals; Interferons; Polyethylene glycols
  • Mechanism of Action Immunostimulants; Interferon alpha stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Hepatitis B; Hepatitis C
  • Phase III Chronic myeloid leukaemia; Essential thrombocythaemia; Hepatitis D; Polycythaemia vera
  • Phase II HIV-1 infections
  • Discontinued Malignant melanoma; Renal cell carcinoma

Most Recent Events

  • 28 Jan 2019 No recent reports of development identified for phase-I development in Hepatitis-C in Hong Kong (SC, Injection)
  • 28 Jan 2019 No recent reports of development identified for phase-I development in Hepatitis-C in Taiwan (SC, Injection)
  • 01 Dec 2018 Peginterferon alfa-2a licensed to Ascletis in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top